US SB3751

Requires the GAO Comptroller General to study price-related compensation and payment structures in the retail prescription drug supply chain, including fee arrangements calculated as percentages of drug prices

Study must examine practices among pharmacy benefit managers, Part D plan sponsors, drug wholesalers, pharmacies, manufacturers, pharmacy services administrative organizations, brokers, consultants, and rebate aggregators

GAO must analyze potential conflicts of interest where percentage-based fees may incentivize selection of higher-priced drugs in formularies, distribution, or purchasing decisions

Study will compare compensation structures between affiliated entities (those with common ownership) and unaffiliated entities, and examine trends across Medicare Part D and Medicaid markets

Report with findings and legislative/administrative recommendations due to Congress within 2 years of enactment